Last reviewed · How we verify
Nicotine polacrilex, Bupropion
Nicotine polacrilex provides nicotine replacement while bupropion inhibits norepinephrine and dopamine reuptake to reduce cravings and withdrawal symptoms during smoking cessation.
Nicotine polacrilex provides nicotine replacement while bupropion inhibits norepinephrine and dopamine reuptake to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation.
At a glance
| Generic name | Nicotine polacrilex, Bupropion |
|---|---|
| Also known as | Nicorette, Zyban |
| Sponsor | University of California, San Francisco |
| Drug class | Nicotine replacement therapy combined with antidepressant |
| Target | Nicotinic acetylcholine receptors (nicotine polacrilex); norepinephrine and dopamine transporters (bupropion) |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | Phase 3 |
Mechanism of action
Nicotine polacrilex is a nicotine replacement therapy that binds to nicotinic acetylcholine receptors to satisfy nicotine dependence and reduce withdrawal. Bupropion is an atypical antidepressant that increases dopamine and norepinephrine levels in the brain, reducing cravings and improving mood during smoking cessation. The combination addresses both the pharmacological and psychological aspects of nicotine addiction.
Approved indications
- Smoking cessation
Common side effects
- Insomnia
- Dry mouth
- Nausea
- Headache
- Dizziness
- Seizures (bupropion-related)
Key clinical trials
- Preoperative Smoking Cessation in Patients Undergoing Surgery (NA)
- Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening (NA)
- The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (PHASE3)
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Metabolism-informed Care for Smoking Cessation (NA)
- A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (PHASE4)
- The Precision CAD Trial (NA)
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: